Articles

Editor's Letter

Published on 28 January 2019

Fourth and final issue of GaBI Journal’s seventh volume

Globalization of the world’s economy has clearly created both major advances and ongoing challenges including in the pharmaceutical industry. Naming of pharmaceuticals might seem to be an uninteresting topic to...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0704.028

2.809 views

Read more →

Abstracted Scientific Content

Published on 03 December 2018

How does generic drug policy affect market prices?

Submitted: 21 November 2018; Revised: 22 November 2018; Accepted: 28 November 2018; Published online first: 4 December 2018 A study published by the World Health Organization (WHO) compares the effect...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0703.027

5.034 views

Read more →

Abstracted Scientific Content

Published on 10 July 2018

EU risk-sharing agreements between 2000−2015

Submitted: 20 June 2018; Revised: 14 August 2018; Accepted: 18 August 2018; Published online first: 31 August 2018 The ageing population, longer life expectancies, and the increasing cost of drugs...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0703.026

3.753 views

Read more →

Meeting Report

Published on 14 June 2018

First ASEAN educational workshop on regulation and approval of biosimilars/similar biotherapeutic products 2017 – Report

Author byline as per print journal: Robin Thorpe, PhD, FRCPath; Elwyn Griffiths, PhD, DSc; Niklas Ekman, PhD Abstract: Biosimilar medicines are being increasingly developed and used worldwide. Many regulatory agencies across...

Author(s): Elwyn Griffiths, DSc, PhD, Niklas Ekman, PhD, Robin Thorpe, PhD, FRCPath

ASEAN, biologicals, biosimilars, education, regulatory, similar biotherapeutic product

DOI: 10.5639/gabij.2018.0703.025

7.115 views

Read more →

Original Research

Published on 01 June 2018

In vitro analytical and antibiotic comparison of generic moxifloxacin against E. coli and S. aureus bacteria strains

Author byline as per print journal: Auxiliary Professor Antistio Alviz-Amador1, MSc, Pharmaceutical Chemist; Jairo E Mercado Camargo2, MSc; Marlene Duran-Lengua3, MSc, PhD, Bacteriologist Introduction: Moxifloxacin is a quinolone antibiotic often used to treat...

Author(s): Antistio Alviz-Amador, MSc, Jairo E Mercado Camargo, MSc, Marlene Duran-Lengua, MSc, PhD

antibiotic resistance, Colombia, E. coli, moxifloxacin, S. aureus

DOI: 10.5639/gabij.2018.0703.024

7.575 views

Read more →

Original Research

Published on 10 July 2018

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina

Introduction and study objectives: Benefit-risk evaluations are essential throughout the life cycle of a drug to guarantee therapeutic efficacy for the authorized indications without an unacceptable incidence of adverse effects....

Author(s): Francisco Fernández, MD, Matías Deprati, MD, Patricia Rodríguez Acedo, Eduardo Spitzer, BSc, Alvaro Romera, MD, Nadia Español, BSc

adverse drug reaction, bevacizumab, biosimilar, monoclonal antibody, pharmacovigilance, safety profile

DOI: 10.5639/gabij.2018.0703.023

12.837 views

Read more →

Original Research

Published on 09 January 2018

Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures

Author byline as per print journal: Victoire Vieillard, PharmD; Professor Alain Astier, PharmD, PhD; Muriel Paul, PharmD Objectives: This study assessed the long-term stability of the trastuzumab biosimilar CT-P6 (Herzuma®, Biogaran)...

Author(s): Muriel Paul, PharmD, Professor Alain Astier, PharmD, PhD, Victoire Vieillard, PharmD

biosimilar, extended stability, in-use stability, trastuzumab

DOI: 10.5639/gabij.2018.0703.022

23.043 views

Read more →

Commentary

Published on 14 June 2018

Medicines regulation in the MENA region and the importance of the World Health Organization’s INN proposal of Biological Qualifier

Author byline as per print journal: Peter J Pitts, BA; Michael S Reilly, Esq Abstract: The World Health Organization should finalize its Biological Qualifier guidance. Distinguishable naming will allow quick and...

Author(s): Michael S Reilly, Esq, Peter J Pitts, BA

Biological Qualifier (BQ), biosimilar, INN, medicines regulation, MENA (Middle East, North Africa), North Africa)

DOI: 10.5639/gabij.2018.0703.021

11.988 views

Read more →

Editor's Letter

Published on 03 December 2018

Latest features in GaBI Journal, 2018, Issue 3

This third issue of GaBI Journal in 2018 contains manuscripts which discuss a number of important, post-marketing, ‘real world’ generic and biosimilar medicinal product issues. In a Commentary, Pitts and...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0703.020

2.809 views

Read more →

Abstracted Scientific Content

Published on 01 June 2018

A call for coherence in EU legislation to promote generics

Submitted: 6 May 2018; Revised: 7 May 2018; Accepted: 8 May 2018; Published online first: 18 May 2018 Data and market exclusivity for originator medicines in the European Union (EU)...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2018.0702.019

3.699 views

Read more →

Opinion

Published on 01 June 2018

Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance

Abstract: Biosimilar drugs have suffered slow entrance and acceptance rates in the US market, due not only to common misperceptions among the public but also US Food and Drug Administration...

Author(s): Adjunct Professor Sarfaraz K Niazi, PhD, SI, FRSB, FPAMS, FACB

analytical similarity, biosimilars, immunogenicity testing, pharmacokinetic profiling

DOI: 10.5639/gabij.2018.0702.018

14.614 views

Read more →